Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Camelia Iancu-Rubin, PhD
Icahn School of Medicine at Mount Sinai
Study Chair - Marina Kremyanskaya, MD, PhD
Icahn School of Medicine at Mount Sinai
Principal Investigator - Nina Bhardwaj, MD, PhD
Icahn School of Medicine at Mount Sinai
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
Marina Kremyanskaya, MD, PhDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Apr 2023
- Primary completion
- 31 Mar 2027
- Completion
- 31 Mar 2027
- Last update posted
- 6 Apr 2025
- Registered enrollment
- 10
- Registry id
- NCT05025488
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.